POST Online Media Lite Edition


Kymera Therapeutics appoints Elena Ridloff to board

Christian Fernsby |
Watertown, Mass., USA - Kymera Therapeutics, a biopharmaceutical company, announced the appointment of Elena Ridloff to its board of directors, where she will serve as chair of the audit committee.

Article continues below

Ms. Ridloff joins Kymera’s Board with two decades of biopharmaceutical industry experience, including senior leadership positions at commercial-stage companies and as an institutional investor.

Ms. Ridloff currently serves as the Executive Vice President, Chief Financial Officer for Acadia Pharmaceuticals Inc.

She joined the company in April 2018 as Senior Vice President, Investor Relations, where she led investor and financial communications activities and since October 2018 has served as Chief Financial Officer.

Prior to joining Acadia, she was Vice President, Investor Relations at Alexion Pharmaceuticals and served as a member of the Operating Committee.

Additionally, Ms. Ridloff was Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm serving the life sciences industry.

Ms. Ridloff was also a Managing Director at Maverick Capital, a hedge fund based in New York, and was responsible for investments in the biotechnology, pharmaceutical, medical device, and life science sectors. She currently serves on the Board of Directors of Kronos Bio, Inc.

LATEST 5 MOVES FROM Massachusetts